Zylox-Tonbridge Medical Technology Co., Ltd. (02190) disclosed changes to its share capital as of 07 November 2025. A total of 50,000 H shares (approximately 0.0155% of its previously issued shares) were repurchased at a highest price of HKD 23.64 and a lowest price of HKD 23.20, with an aggregate payment of HKD 1,171,660. These repurchased shares are held as treasury shares, increasing the treasury share count to 6,846,131.

The company also issued 7,270,000 new shares to a director and 6,680,000 new shares to other participants under its 2025 Share Incentive Scheme at RMB 1 per share. Following these changes, the total number of issued shares (excluding treasury shares) rose from 315,604,613 to 329,504,613, and inclusive of treasury shares the closing balance stands at 336,350,744.